Seattle Genetics, Inc. (SGEN) Shares Bought by Shell Asset Management Co.

Share on StockTwits

Shell Asset Management Co. increased its holdings in Seattle Genetics, Inc. (NASDAQ:SGEN) by 19.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 7,364 shares of the biotechnology company’s stock after purchasing an additional 1,198 shares during the period. Shell Asset Management Co.’s holdings in Seattle Genetics were worth $568,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd purchased a new position in Seattle Genetics in the third quarter worth about $104,000. OLD Mutual Customised Solutions Proprietary Ltd. purchased a new position in shares of Seattle Genetics during the 2nd quarter valued at about $139,000. Hollencrest Capital Management purchased a new position in shares of Seattle Genetics during the 3rd quarter valued at about $216,000. Fox Run Management L.L.C. purchased a new position in shares of Seattle Genetics during the 3rd quarter valued at about $225,000. Finally, Crossmark Global Holdings Inc. purchased a new position in shares of Seattle Genetics during the 2nd quarter valued at about $223,000.

NASDAQ:SGEN opened at $59.99 on Friday. Seattle Genetics, Inc. has a 1 year low of $47.75 and a 1 year high of $84.37.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings data on Thursday, October 25th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.15). Seattle Genetics had a negative return on equity of 19.13% and a negative net margin of 26.58%. The firm had revenue of $169.42 million during the quarter, compared to the consensus estimate of $164.75 million. On average, sell-side analysts predict that Seattle Genetics, Inc. will post -1.44 EPS for the current year.

In other Seattle Genetics news, insider Vaughn B. Himes sold 5,000 shares of Seattle Genetics stock in a transaction that occurred on Friday, November 30th. The stock was sold at an average price of $62.14, for a total value of $310,700.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Clay B. Siegall sold 20,148 shares of Seattle Genetics stock in a transaction that occurred on Monday, October 8th. The stock was sold at an average price of $77.39, for a total value of $1,559,253.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 76,611 shares of company stock worth $5,334,380. Corporate insiders own 33.80% of the company’s stock.

A number of research analysts recently commented on the company. ValuEngine cut Seattle Genetics from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 27th. Zacks Investment Research raised Seattle Genetics from a “hold” rating to a “buy” rating and set a $85.00 price target on the stock in a report on Thursday, August 23rd. Needham & Company LLC lowered their price target on Seattle Genetics to $73.00 and set a “buy” rating on the stock in a report on Friday, October 26th. Cann reissued a “hold” rating on shares of Seattle Genetics in a report on Monday, October 1st. Finally, BidaskClub cut Seattle Genetics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 9th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $77.77.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by BBNS and is owned by of BBNS. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/12/08/seattle-genetics-inc-sgen-shares-bought-by-shell-asset-management-co/3065444.html.

Seattle Genetics Company Profile

Seattle Genetics, Inc, a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.

Read More: What is a Stop Order?

Want to see what other hedge funds are holding SGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seattle Genetics, Inc. (NASDAQ:SGEN).

Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.